Citi Pharma Statistics

Total Valuation

Citi Pharma has a market cap or net worth of PKR 19.09 billion. The enterprise value is 20.71 billion.

Market Cap	19.09B
Enterprise Value	20.71B

Important Dates

The last earnings date was Tuesday, April 29, 2025.

Earnings Date	Apr 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Citi Pharma has 228.46 million shares outstanding. The number of shares has increased by 0.01% in one year.

Current Share Class	228.46M
Shares Outstanding	228.46M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	52.11%
Owned by Institutions (%)	12.07%
Float	101.56M

Valuation Ratios

The trailing PE ratio is 22.97.

PE Ratio	22.97
Forward PE	n/a
PS Ratio	1.47
PB Ratio	3.43
P/TBV Ratio	3.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.21, with an EV/FCF ratio of -18.91.

EV / Earnings	24.93
EV / Sales	1.60
EV / EBITDA	14.21
EV / EBIT	16.03
EV / FCF	-18.91

Financial Position

The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.53.

Current Ratio	1.24
Quick Ratio	0.62
Debt / Equity	0.53
Debt / EBITDA	2.02
Debt / FCF	-2.69
Interest Coverage	3.96

Financial Efficiency

Return on equity (ROE) is 15.04% and return on invested capital (ROIC) is 10.55%.

Return on Equity (ROE)	15.04%
Return on Assets (ROA)	6.69%
Return on Invested Capital (ROIC)	10.55%
Return on Capital Employed (ROCE)	22.19%
Revenue Per Employee	25.00M
Profits Per Employee	1.60M
Employee Count	519
Asset Turnover	1.07
Inventory Turnover	3.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +162.79% in the last 52 weeks. The beta is 0.58, so Citi Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.58
52-Week Price Change	+162.79%
50-Day Moving Average	88.58
200-Day Moving Average	63.31
Relative Strength Index (RSI)	49.64
Average Volume (20 Days)	3,188,672

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Citi Pharma had revenue of PKR 12.97 billion and earned 830.91 million in profits. Earnings per share was 3.64.

Revenue	12.97B
Gross Profit	1.70B
Operating Income	1.29B
Pretax Income	1.19B
Net Income	830.91M
EBITDA	1.45B
EBIT	1.29B
Earnings Per Share (EPS)	3.64

Full Income Statement

Balance Sheet

The company has 1.32 billion in cash and 2.94 billion in debt, giving a net cash position of -1.62 billion or -7.11 per share.

Cash & Cash Equivalents	1.32B
Total Debt	2.94B
Net Cash	-1.62B
Net Cash Per Share	-7.11
Equity (Book Value)	5.57B
Book Value Per Share	24.26
Working Capital	1.90B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -913.66 million and capital expenditures -181.62 million, giving a free cash flow of -1.10 billion.

Operating Cash Flow	-913.66M
Capital Expenditures	-181.62M
Free Cash Flow	-1.10B
FCF Per Share	-4.79

Full Cash Flow Statement

Margins

Gross margin is 13.10%, with operating and profit margins of 9.96% and 6.40%.

Gross Margin	13.10%
Operating Margin	9.96%
Pretax Margin	9.19%
Profit Margin	6.40%
EBITDA Margin	11.21%
EBIT Margin	9.96%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 3.25, which amounts to a dividend yield of 3.92%.

Dividend Per Share	3.25
Dividend Yield	3.92%
Dividend Growth (YoY)	30.00%
Years of Dividend Growth	3
Payout Ratio	89.39%
Buyback Yield	-0.01%
Shareholder Yield	3.91%
Earnings Yield	4.35%
FCF Yield	-5.74%

Dividend Details

Stock Splits

The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.

Last Split Date	Oct 18, 2021
Split Type	Forward
Split Ratio	1.1

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a